Hao-Wei Wang

Hao-Wei Wang

Auto-generated profile, based on publicly available information

Hao-Wei Wang

National Institutes of Health

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2010 in Genes & Development
Verified
Journal Article
Closed access
PDF file
VGVasilena Gocheva
Vasilena Gocheva
HWHao-Wei Wang
Hao-Wei Wang
BGBedrick B. Gadea
Bedrick B. Gadea
TSTanaya Shree
Tanaya Shree
KHKaren E. Hunter
Karen E. Hunter
JJJohanna A. Joyce
Johanna A. Joyce
Innate immune cells can constitute a substantial proportion of the cells within the tumor microenvironment and have been associated with tumor malignancy in patients and animal models of cancer; however, the mechanisms by which they modulate cancer progression are incompletely understood. Here, we show that high levels of cathepsin protease activity are induced in the majority of macrophages in the microenvironment of pancreatic islet cancers, mammary tumors, and lung metastases during malignant progression. We further show that tumor-associated macrophage (TAM)-supplied cathepsins B and S are critical for promoting pancreatic tumor growth, angiogenesis, and invasion in vivo, and markedly enhance the invasiveness of cancer cells in culture. Finally, we demonstrate that interleukin-4 (IL-4) is responsible for inducing cathepsin activity in macrophages in vitro and in vivo. Together, these data establish IL-4 as an important regulator, and cathepsin proteases as critical mediators, of the cancer-promoting functions of TAMs.

14 April 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NSNirali N. Shah
Nirali N. Shah
SHSteven L. Highfill
Steven L. Highfill
HSHaneen Shalabi
Haneen Shalabi
BYBonnie Yates
Bonnie Yates
JJJianjian Jin
Jianjian Jin
TFTerry J. Fry
Terry J. Fry
PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort treated with CD22 chimeric antigen receptor (CAR) T cells. PATIENTS AND METHODS: We conducted a single-center, phase I, 3 + 3 dose-escalation trial with a large expansion cohort that tested CD22-targeted CAR T cells for children and young adults with relapsed/refractory CD22+ malignancies. Primary objectives were to assess the safety, toxicity, and feasibility. Secondary objectives included efficacy, CD22 CAR T-cell persistence, and cytokine profiling. RESULTS: Fifty-eight participants were infused; 51 (87.9%) after prior CD19-targeted therapy. Cytokine release syndrome occurred in 50 participants (86.2%) and was grade 1-2 in 45 (90%). Symptoms of neurotoxicity were minimal and transient. Hemophagocytic lymphohistiocytosis–like manifestations were seen in 19/58 (32.8%) of subjects, prompting utilization of anakinra. CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission rate was 70%. The median overall survival was 13.4 months (95% CI, 7.7 to 20.3 months). Among those who achieved a complete response, the median relapse-free survival was 6.0 months (95% CI, 4.1 to 6.5 months). Thirteen participants proceeded to stem-cell transplantation. CONCLUSION: In the largest experience of CD22 CAR T-cells to our knowledge, we provide novel information on the impact of manufacturing changes on clinical outcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies. The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy.

1 September 2016 in Cell Reports
Verified
Journal Article
Open access
DYDongyao Yan
Dongyao Yan
HWHao-Wei Wang
Hao-Wei Wang
RBRobert L. Bowman
Robert L. Bowman
JJJohanna A. Joyce
Johanna A. Joyce
Tumor-associated macrophages play critical roles during tumor progression by promoting angiogenesis, cancer cell proliferation, invasion, and metastasis. Cysteine cathepsin proteases, produced by macrophages and cancer cells, modulate these processes, but it remains unclear how these typically lysosomal enzymes are regulated and secreted within the tumor microenvironment. Here, we identify a STAT3 and STAT6 synergy that potently upregulates cathepsin secretion by macrophages via engagement of an unfolded protein response (UPR) pathway. Whole-genome expression analyses revealed that the TH2 cytokine interleukin (IL)-4 synergizes with IL-6 or IL-10 to activate UPR via STAT6 and STAT3. Pharmacological inhibition of the UPR sensor IRE1α blocks cathepsin secretion and blunts macrophage-mediated cancer cell invasion. Similarly, genetic deletion of STAT3 and STAT6 signaling components impairs tumor development and invasion in vivo. Together, these findings demonstrate that cytokine-activated STAT3 and STAT6 cooperate in macrophages to promote a secretory phenotype that enhances tumor progression in a cathepsin-dependent manner.

8 November 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
HWHao‐Wei Wang
Hao‐Wei Wang
JBJayalakshmi P. Balakrishna
Jayalakshmi P. Balakrishna
SPStefania Pittaluga
Stefania Pittaluga
Elaine JaffeElaine Jaffe
Elaine Jaffe

1 February 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
HSHaneen Shalabi
Haneen Shalabi
IKIra L. Kraft
Ira L. Kraft
HWHao-Wei Wang
Hao-Wei Wang
CYConstance M. Yuan
Constance M. Yuan
BYBonnie Yates
Bonnie Yates
NSNirali N. Shah
Nirali N. Shah
Chimeric antigen receptor (CAR) T cell therapy using an anti-CD19 binding domain has been shown to be effective in adults with lymphoma and may represent an alternative treatment strategy in pediatric lymphoma, although experience in this younger age group is limited. Loss of the target antigen, as a mechanism of tumor escape following immunotherapy, is an increasingly recognized phenomena which has limited the efficacy of immunotherapy in leukemia, however little is known about antigen loss in lymphoma. We present a case of a pediatric patient with multiply relapsed advanced stage DLBCL who developed sequential antigen loss disease following sequential CAR immunotherapy. This case provides a proof of concept of antigen loss as a mechanism for relapse following immunotherapy in lymphomas, and highlights the need for repeat biopsy and flow cytometric analysis in guiding sequential immunotherapeutic interventions.

15 December 2010 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
HWHao-Wei Wang
Hao-Wei Wang
JJJohanna A. Joyce
Johanna A. Joyce
Although macrophages were originally recognized as major immune effector cells, it is now appreciated that they also play many important roles in the maintenance of tissue homeostasis, and are involved in a variety of pathological conditions including cancer. Several studies have demonstrated the contributions of tumor-associated macrophages (TAMs) to tumor initiation, progression, and metastasis. However, the detailed mechanisms underlying how TAMs differ molecularly from their normal counterparts and how the conversion to TAMs occurs have only just begun to be understood. TAMs have been proposed to exhibit phenotypes of ‘alternatively activated’ macrophages, though there has been limited evidence directly linking the phenotypes of TAMs to the alternative activation of macrophages. This review will focus on IL-4, the prototypic cytokine that induces the alternative activation of macrophages, and review current knowledge regarding the contributions of IL-4 to the phenotypes of TAMs and its effects on tumorigenesis.